GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using FreeStyle Libre 2 (FSL2) for Preventing Hyperglycemia/Hypoglycemia Crisis in Advanced Oncological Patients.

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 118 participants.

Also called NCT04942756

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose supportive care
Phase
Not applicable
Enrolled
  • 118 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04942756
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Israel, Italy, Switzerland (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04942756. Randomized; no masking; primary purpose supportive care. Start 2021-06-30 (actual); primary completion 2022-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using FreeStyle Libre 2 (FSL2) for Preventing Hyperglycemia/Hypoglycemia Crisis in Advanced Oncological Patients.
Condition
Palliative Care
Condition
Diabetes Mellitus, Type 2
Condition
Diabetes Mellitus, Type 1
Condition
Diabetes
Condition
Cancer
Condition
Terminal Cancer
Condition
Terminal Illness
Condition
End Stage Cancer
Condition
Advanced Cancer
Intervention (Device)
Continuous Glucose Monitoring
Intervention (Device)
Standard Care
Lead sponsor
Antea Foundation (class: other)
Collaborator
Abbott Diabetes Care (class: industry)

Record details

Record id
cardio:ct-nct04942756
Content hash
5a85e533520624f27cb311c30ab9c89d151fc7c2c39a2148cf67054fbd5bcaba